Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In this interview with Oncology Data Advisor, Dr. Matthew Davids of Harvard Medical School delves further into the latest research in p53-directed therapeutic strategies and the future of targeting this specific mutation.

Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc

Oncology Data Advisor®